Research advances in microsomal prostaglandin E<sub>2</sub> synthase-1 targeted anti-inflammatory drugs

JI Shuang; CHEN Lihong

doi:10.11665/j.issn.1000-5048.2023032001

Journal of China Pharmaceutical University > 2024 > 55(5): 697-707. > DOI: 10.11665/j.issn.1000-5048.2023032001

JI Shuang, CHEN Lihong. Research advances in microsomal prostaglandin E₂ synthase-1 targeted anti-inflammatory drugs[J]. J China Pharm Univ, 2024, 55(5): 697 − 707. DOI: 10.11665/j.issn.1000-5048.2023032001

Citation:

PDF (852 KB)

Research advances in microsomal prostaglandin E₂ synthase-1 targeted anti-inflammatory drugs

JI Shuang,
CHEN Lihong^,

Advanced Institute for Medical Sciences, Dalian Medical University, Dalian 116044, China

Funds: This study was supported by the National Natural Science Foundation of China (No. 32071157, No.31900142); and the Doctoral Scientific Research Foundation of Liaoning Province (2020-BS-202)

More Information

Received Date: March 19, 2023

Graphical Abstract

Abstract

Abstract

Microsomal prostaglandin E₂ synthase 1 (mPGES-1), the main terminal synthase of prostaglandin E₂ (PGE₂), plays a crucial role in inflammatory diseases. Compared to non-steroidal anti-inflammatory drugs (NSAIDs), mPGES-1 inhibitors are promising agents for their better specificity and higher safety. This article summarizes the research status of mPGES-1 in inflammation and cardiovascular diseases, systematically reviews the research progress of the development of mPGES-1 inhibitors, elaborates on their therapeutic effects in different inflammation animal models and inflammatory diseases, and discusses the possible existing challenges, aiming to provide some guidance and reference for the subsequent research of anti-inflammatory drugs.
- non-steroidal anti-inflammatory drugs,
- prostaglandin E₂,
- mPGES-1,
- inflammatory diseases

FullText(HTML)

References (54)

References

[1]	Hoxha M. What about COVID-19 and arachidonic acid pathway[J]? Eur J Clin Pharmacol, 2020, 76(11): 1501-1504. doi: 10.1007/s00228-020-02941-w
[2]	Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far[J]. Front Immunol, 2020, 11: 1446. doi: 10.3389/fimmu.2020.01446
[3]	Mazaleuskaya LL, Ricciotti E. Druggable prostanoid pathway[J]. Adv Exp Med Biol, 2020, 1274: 29-54.
[4]	Ahmadi M, Bekeschus S, Weltmann KD, et al. Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors[J]. RSC Med Chem, 2022, 13(5): 471-496. doi: 10.1039/D1MD00280E
[5]	Neuschäfer-Rube F, Schön T, Kahnt I, et al. LDL-dependent regulation of TNFα/PGE₂ induced COX-2/mPGES-1 expression in human macrophage cell lines[J]. Inflammation, 2023, 46(3): 893-911. doi: 10.1007/s10753-022-01778-y
[6]	Tuure L, Hämäläinen M, Nummenmaa E, et al. Downregulation of microsomal prostaglandin E synthase-1 (mPGES-1) expression in chondrocytes is regulated by MAP kinase phosphatase-1 (MKP-1)[J]. Int Immunopharmacol, 2019, 71: 139-143. doi: 10.1016/j.intimp.2019.03.014
[7]	Terzuoli E, Costanza F, Ciccone V, et al. mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines[J]. Prostaglandins Other Lipid Mediat, 2019, 143: 106344. doi: 10.1016/j.prostaglandins.2019.106344
[8]	Wang C, Li SL, Wang Y, et al. Targeting IRS-1/mPGES-1/NOX2 to inhibit the inflammatory response caused by insulin-like growth factor-I-induced activation of NF-κB and NLRP3 in cancer cells[J]. Vet Comp Oncol, 2020, 18(4): 689-698. doi: 10.1111/vco.12596
[9]	Sluter MN, Li QQ, Yasmen N, et al. The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders[J]. Exp Biol Med, 2023, 248(9): 811-819. doi: 10.1177/15353702231179926
[10]	Sluter MN, Bhuniya R, Yuan XR, et al. Novel, brain-permeable, cross-species benzothiazole inhibitors of microsomal prostaglandin E synthase-1 (mPGES-1) dampen neuroinflammation in vitro and in vivo[J]. ACS Pharmacol Transl Sci, 2023, 6(4): 587-599. doi: 10.1021/acsptsci.2c00241
[11]	Stewart MJ, Weaver LM, Ding K, et al. Analgesic effects of a highly selective mPGES-1 inhibitor[J]. Sci Rep, 2023, 13(1): 3326. doi: 10.1038/s41598-023-30164-3
[12]	Xu YF, Liu Y, Li KX, et al. COX-2/PGE₂ pathway inhibits the ferroptosis induced by cerebral ischemia reperfusion[J]. Mol Neurobiol, 2022, 59(3): 1619-1631. doi: 10.1007/s12035-021-02706-1
[13]	Yang GR, Chen LH. An update of microsomal prostaglandin E synthase-1 and PGE₂ receptors in cardiovascular health and diseases[J]. Oxid Med Cell Longev, 2016, 2016: 5249086. doi: 10.1155/2016/5249086
[14]	Weaver LM, Loftin CD, Zhan CG. Development of pharmacotherapies for abdominal aortic aneurysms[J]. Biomedecine Pharmacother, 2022, 153: 113340. doi: 10.1016/j.biopha.2022.113340
[15]	Chen LH, Yang GR, Jiang TT, et al. Myeloid cell mPGES-1 deletion attenuates mortality without affecting remodeling after acute myocardial infarction in mice[J]. J Pharmacol Exp Ther, 2019, 370(1): 18-24. doi: 10.1124/jpet.118.256057
[16]	Steinmetz-Späh J, Arefin S, Larsson K, et al. Effects of microsomal prostaglandin E synthase-1 inhibition on resistance artery tone in patients with end stage kidney disease[J]. Br J Pharmacol, 2022, 179(7): 1433-1449. doi: 10.1111/bph.15729
[17]	Zhu LY, Xu CS, Huo XY, et al. The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury[J]. Nat Commun, 2019, 10(1): 1888. doi: 10.1038/s41467-019-09492-4
[18]	Duivenvoorden R, Tang J, Cormode DP, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation[J]. Nat Commun, 2014, 5: 3065. doi: 10.1038/ncomms4065
[19]	Dos Santos Nascimento IJ, de Aquino TM, da Silva Júnior EF. Computer-aided drug design of anti-inflammatory agents targeting microsomal prostaglandin E₂ synthase-1 (mPGES-1)[J]. Curr Med Chem, 2022, 29(33): 5397-5419. doi: 10.2174/0929867329666220317122948
[20]	Finetti F, Terzuoli E, Giachetti A, et al. mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity[J]. Endocr Relat Cancer, 2015, 22(4): 665-678. doi: 10.1530/ERC-15-0277
[21]	Muthukaman N, Deshmukh S, Sarode N, et al. Discovery of 2-((2-chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7, 8-dihydro-1H-[1, 4]dioxino[2', 3': 3, 4]benzo[1, 2-d]imidazole-5-carboxamide as potent, selective and efficacious microsomal prostaglandin E₂ synthase-1 (mPGES-1) inhibitor[J]. Bioorg Med Chem Lett, 2016, 26(24): 5977-5984. doi: 10.1016/j.bmcl.2016.10.079
[22]	Muthukaman N, Tambe M, Deshmukh S, et al. Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: part-1[J]. Bioorg Med Chem Lett, 2017, 27(23): 5131-5138. doi: 10.1016/j.bmcl.2017.10.062
[23]	Muthukaman N, Deshmukh S, Tambe M, et al. Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: part-2[J]. Bioorg Med Chem Lett, 2018, 28(7): 1211-1218. doi: 10.1016/j.bmcl.2018.02.048
[24]	Bergqvist F, Ossipova E, Idborg H, et al. Inhibition of mPGES-1 or COX-2 results in different proteomic and lipidomic profiles in A549 lung cancer cells[J]. Front Pharmacol, 2019, 10: 636. doi: 10.3389/fphar.2019.00636
[25]	Rappl P, Rösser S, Maul P, et al. Inhibition of mPGES-1 attenuates efficient resolution of acute inflammation by enhancing CX3CL1 expression[J]. Cell Death Dis, 2021, 12(2): 135. doi: 10.1038/s41419-021-03423-2
[26]	Bergqvist F, Carr AJ, Wheway K, et al. Divergent roles of prostacyclin and PGE₂ in human tendinopathy[J]. Arthritis Res Ther, 2019, 21(1): 74. doi: 10.1186/s13075-019-1855-5
[27]	Larsson K, Steinmetz J, Bergqvist F, et al. Biological characterization of new inhibitors of microsomal PGE synthase-1 in preclinical models of inflammation and vascular tone[J]. Br J Pharmacol, 2019, 176(24): 4625-4638. doi: 10.1111/bph.14827
[28]	Wu F, Wen ZC, Zhi ZK, et al. MPGES-1 derived PGE₂ inhibits cell migration by regulating ARP2/3 in the pathogenesis of Hirschsprung disease[J]. J Pediatr Surg, 2019, 54(10): 2032-2037. doi: 10.1016/j.jpedsurg.2019.01.001
[29]	Koeberle A, Haberl EM, Rossi A, et al. Discovery of benzo[ g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1[J]. Bioorg Med Chem, 2009, 17(23): 7924-7932. doi: 10.1016/j.bmc.2009.10.025
[30]	Wang J, Limburg D, Carter J, et al. Selective inducible microsomal prostaglandin E₂ synthase-1 (mPGES-1) inhibitors derived from an oxicam template[J]. Bioorg Med Chem Lett, 2010, 20(5): 1604-1609. doi: 10.1016/j.bmcl.2010.01.060
[31]	Raucci F, Saviano A, Casillo GM, et al. IL-17-induced inflammation modulates the mPGES-1/PPAR-γ pathway in monocytes/macrophages[J]. Br J Pharmacol, 2022, 179(9): 1857-1873. doi: 10.1111/bph.15413
[32]	Guerrero MD, Aquino M, Bruno I, et al. Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression[J]. Eur J Pharmacol, 2009, 620(1/2/3): 112-119.
[33]	Koeberle A, Rossi A, Zettl H, et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2, 3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E₂ synthase-1 and 5-lipoxygenase[J]. J Pharmacol Exp Ther, 2010, 332(3): 840-848. doi: 10.1124/jpet.109.160663
[34]	Hieke M, Greiner C, Thieme TM, et al. A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold[J]. Bioorg Med Chem Lett, 2011, 21(5): 1329-1333. doi: 10.1016/j.bmcl.2011.01.049
[35]	Finetti F, Terzuoli E, Bocci E, et al. Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis[J]. PLoS One, 2012, 7(7): e40576. doi: 10.1371/journal.pone.0040576
[36]	dos Santos LD, Froes TQ, Contin de Melo MC, et al. Triazol-phenyl antipyretic derivatives inhibit mPGES-1 mRNA levels in LPS-induced RAW 264.7 macrophage cells[J]. Antiinflamm Antiallergy Agents Med Chem, 2021, 20(3): 271-281. doi: 10.2174/1871523019999201208202831
[37]	Lee HH, Moon Y, Shin JS, et al. A novel mPGES-1 inhibitor alleviates inflammatory responses by downregulating PGE₂ in experimental models[J]. Prostaglandins Other Lipid Mediat, 2019, 144: 106347. doi: 10.1016/j.prostaglandins.2019.106347
[38]	Kim M, Kim G, Kang MJ, et al. Discovery of N-amido-phenylsulfonamide derivatives as novel microsomal prostaglandin E₂ synthase-1 (mPGES-1) inhibitors[J]. Bioorg Med Chem Lett, 2021, 41: 127992. doi: 10.1016/j.bmcl.2021.127992
[39]	Weaver LM, Stewart MJ, Ding K, et al. A highly selective mPGES-1 inhibitor to block abdominal aortic aneurysm progression in the angiotensin mouse model[J]. Sci Rep, 2024, 14(1): 6959. doi: 10.1038/s41598-024-57437-9
[40]	Shin JS, Choi HE, Kim SD, et al. Anti-inflammatory effects of 7-hydroxyl-1-methylindole-3-acetonitrile, a synthetic arvelexin derivative, on the macrophages through destabilizing mPGES-1 mRNA and suppressing NF-κB activation[J]. Chem Biol Interact, 2014, 224: 68-77. doi: 10.1016/j.cbi.2014.10.004
[41]	Koeberle A, Bauer J, Verhoff M, et al. Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1[J]. Biochem Biophys Res Commun, 2009, 388(2): 350-354. doi: 10.1016/j.bbrc.2009.08.005
[42]	Koeberle A, Pollastro F, Northoff H, et al. Myrtucommulone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1[J]. Br J Pharmacol, 2009, 156(6): 952-961. doi: 10.1111/j.1476-5381.2009.00070.x
[43]	Cárdeno A, Sánchez-Hidalgo M, Aparicio-Soto M, et al. Extra virgin olive oil polyphenolic extracts downregulate inflammatory responses in LPS-activated murine peritoneal macrophages suppressing NFκB and MAPK signalling pathways[J]. Food Funct, 2014, 5(6): 1270-1277. doi: 10.1039/C4FO00014E
[44]	Terzuoli E, Donnini S, Giachetti A, et al. Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis[J]. Clin Cancer Res, 2010, 16(16): 4207-4216. doi: 10.1158/1078-0432.CCR-10-0156
[45]	Castejón ML, Rosillo MÁ, Montoya T, et al. Oleuropein down-regulated IL-1β-induced inflammation and oxidative stress in human synovial fibroblast cell line SW982[J]. Food Funct, 2017, 8(5): 1890-1898. doi: 10.1039/C7FO00210F
[46]	Olajide OA, Kumar A, Velagapudi R, et al. Punicalagin inhibits neuroinflammation in LPS-activated rat primary microglia[J]. Mol Nutr Food Res, 2014, 58(9): 1843-1851. doi: 10.1002/mnfr.201400163
[47]	Siemoneit U, Koeberle A, Rossi A, et al. Inhibition of microsomal prostaglandin E₂ synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense[J]. Br J Pharmacol, 2011, 162(1): 147-162. doi: 10.1111/j.1476-5381.2010.01020.x
[48]	Lio CK, Luo JF, Shen XY, et al. Nardosinanone N suppresses LPS-induced macrophage activation by modulating the Nrf2 pathway and mPGES-1[J]. Biochem Pharmacol, 2020, 173: 113639. doi: 10.1016/j.bcp.2019.113639
[49]	Hung YL, Wang SC, Suzuki K, et al. Bavachin attenuates LPS-induced inflammatory response and inhibits the activation of NLRP3 inflammasome in macrophages[J]. Phytomedicine, 2019, 59: 152785. doi: 10.1016/j.phymed.2018.12.008
[50]	Huang QQ, Lai TL, Wang Q, et al. mPGES-1 inhibitor discovery based on computer-aided screening: pharmacophore models, molecular docking, ADMET, and MD simulations[J]. Molecules, 2023, 28(16): 6059. doi: 10.3390/molecules28166059
[51]	Zhang YY, Yao YD, Luo JF, et al. Microsomal prostaglandin E₂ synthase-1 and its inhibitors: molecular mechanisms and therapeutic significance[J]. Pharmacol Res, 2022, 175: 105977. doi: 10.1016/j.phrs.2021.105977
[52]	Gurusamy M, Nasseri S, Rampa DR, et al. Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice[J]. J Transl Med, 2021, 19(1): 340. doi: 10.1186/s12967-021-03016-9
[53]	Tornling G, Edenius C, Pauling JD, et al. A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud’s[J]. Rheumatology, 2024keae049.
[54]	Bergqvist F, Morgenstern R, Jakobsson PJ. A review on mPGES-1 inhibitors: from preclinical studies to clinical applications[J]. Prostaglandins Other Lipid Mediat, 2020, 147: 106383. doi: 10.1016/j.prostaglandins.2019.106383